Polyrizon Ltd. (PLRZ) SEC Filings — 2025
39 SEC filings for Polyrizon Ltd. (PLRZ) in 2025.
Filings
- Polyrizon Ltd. 6-K Filing — 6-K · Dec 29, 2025
- Polyrizon seeks FDA designation for viral blocker — 6-K · Dec 19, 2025
- Polyrizon Ltd. Advances Intranasal Naloxone Hydrogel Program — 6-K · Dec 11, 2025
- Polyrizon Ltd. Completes FDA Pre-Submission Meeting for Allergy Blocker — 6-K · Dec 8, 2025
- Polyrizon Ltd. Prices $5M Direct Offering at Premium — 6-K · Dec 5, 2025
- Polyrizon Reports Positive Naloxone Hydrogel Mucoadhesion Results — 6-K · Dec 3, 2025
- Polyrizon Ltd. Upscales Nasal Spray Manufacturing — 6-K · Dec 2, 2025
- Polyrizon Ltd. 6-K Filing — 6-K · Nov 25, 2025
- Polyrizon Ltd. Reports Viral Blocking Breakthrough — 6-K · Nov 6, 2025
- Polyrizon Ltd. Reports Positive Pre-Clinical Results for PL-14 — 6-K · Oct 6, 2025
- Polyrizon Submits FDA Pre-Sub Package for Allergy Blocker — 6-K · Sep 19, 2025
- Polyrizon Ltd. Files 6-K with Financials — 6-K · Sep 17, 2025
- Polyrizon Ltd. Shareholders Approve All Proposals — 6-K · Sep 4, 2025
- Polyrizon Ltd. Regains Nasdaq Listing Compliance — 6-K · Aug 14, 2025
- Polyrizon Ltd. Calls Special Shareholder Meeting for Sept 4 — 6-K · Jul 31, 2025
- Polyrizon Ltd. Reports Successful Allergy Blocker Study — 6-K · Jul 22, 2025
- Polyrizon Ltd. Retains Nasdaq Listing — 6-K · Jul 15, 2025
- Polyrizon Ltd. Director Resigns — 6-K · Jun 30, 2025
- Polyrizon Reports Promising CNS Drug Delivery Results — 6-K · Jun 12, 2025
- Polyrizon Ltd. Receives Nasdaq Delisting Notice — 6-K · May 23, 2025
- Polyrizon Ltd. Announces 1-for-250 Reverse Stock Split — 6-K · May 22, 2025
- Polyrizon Ltd. Reports Positive Preclinical Data on Nasal Protection — 6-K · May 21, 2025
- Polyrizon Ltd. Share Count Rises After Warrant Exercises — 6-K · May 19, 2025
- Polyrizon Ltd.: Selling Shareholders Exercise Warrants Post-Registration — 6-K · May 14, 2025
- Polyrizon Ltd. Announces 1-for-10 Reverse Stock Split — 6-K · May 1, 2025
- Polyrizon Reports Successful Safety Study of Allergy Blocker — 6-K · Apr 25, 2025
- Polyrizon Ltd. Shareholders Approve All 14 Proposals at AGM — 6-K · Apr 17, 2025
- Polyrizon Ltd. Gets Nasdaq Minimum Bid Price Warning — 6-K · Apr 11, 2025
- Polyrizon Ltd. Hires Branding Firm for Strategic Development — 6-K · Apr 2, 2025
- Polyrizon Ltd. Raises $17M in Private Placement — 6-K · Apr 1, 2025
- Polyrizon Structures Allergy Blocker Clinical Strategy for FDA Meeting — 6-K · Mar 27, 2025
- Polyrizon Ltd. Expands Epilepsy Drug Delivery Research — 6-K · Mar 25, 2025
- Polyrizon Ltd. Eyes Psychedelic Treatments with New LOI — 6-K · Mar 14, 2025
- Polyrizon Ltd. Schedules Annual Shareholder Meeting for April 17 — 6-K · Mar 13, 2025
- Polyrizon Ltd. Files 2024 Annual Report — 20-F · Mar 11, 2025
- Polyrizon starts naloxone preclinical studies for opioid overdose — 6-K · Mar 10, 2025
- Polyrizon Files Patent for Trap & Target™ Drug Delivery — 6-K · Jan 30, 2025
- Polyrizon Starts GMP Mfg for Allergy Blocker — 6-K · Jan 23, 2025
- Polyrizon Ltd. Appoints Liron Carmel to Board — 6-K · Jan 21, 2025